Casper represents clients in complex business transactions and advises them on general corporate and governance matters.

Casper has significant experience in assisting companies listed in the Netherlands or elsewhere with the corporate law aspects of domestic or cross-border transactions, spin-offs and securities offerings.

Casper's recent work includes advising:

  • Arya Sciences Acquisition Corp. on its joint venture with Immatics Biotechnologies GmbH and its listing on NASDAQ
  • TechnipFMC on the separation and Euronext Paris listing of its Technip Energies business
  • Qiagen on the USD 12.5 billion offer of Thermo Fisher Scientific
  • Pfizer on the USD 22 billion merger of spin-offs Upjohn and Mylan
  • RELX on the discontinuation of its dual-headed structure
  • CB&I on its USD 6 billion combination with McDermott
  • Elastic on its IPO on NYSE
  • Signify on its IPO on Euronext Amsterdam
  • Avast on its acquisition of NYSE-listed AVG Technologies
  • Prosensa on its IPO on Nasdaq and the subsequent USD 840 million offer by Biomarin
  • NXP on its acquisition of NASDAQ-listed Freescale Semiconductors
  • ABN AMRO Group on its IPO on Euronext Amsterdam and the subsequent simplification of its group structure
  • Rabobank on the listing of its depositary receipts on Euronext Amsterdam


  • Profession

    Kandidaat-Notaris (Candidate civil law notary)

  • Languages

    Dutch, English

  • Education

    University of Amsterdam

    Radboud University of Nijmegen

    Seconded to Cravath Swaine & Moore, LLP in 2016 and 2017